Monitor for upcoming 10-K or 8-K filings for potential disclosures on executive departures, slowed development timelines, or lack of partnership progress. Consider this insider selling as a cautionary signal, especially given the concentration among C-suite executives.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 23 $15.56entry
- T+1 · 9mo ago +1.35%α +0.61% · $15.77
- T+5 · 9mo ago +3.21%α +2.59% · $16.06
- T+20 · 8mo ago +6.68%α +10.63% · $16.60
- T+60 · 6mo ago +71.98%α +63.73% · $26.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple C-suite executives at KalVista Pharmaceuticals (KALV) sold shares in a concentrated 7-day window, including the Chief Development Officer, CFO, and Chief Commercial Officer, realizing over $157,000 in total proceeds. The transactions include both cash sales and share movements (M) with no stated value, suggesting possible pre-arranged 10b5-1 plans or equity settlements. The cluster of insider selling by top executives raises caution despite lack of explicit negative filing disclosures.
Key Financial Metrics
Key Facts
- Chief Development Officer Christopher Yea sold 4,347 shares for $67,669.
- CFO Brian Piekos sold 1,767 shares for $27,507.
- Chief Commercial Officer Nicole Sweeny sold 3,975 shares for $61,878.
- Total cash proceeds from insider sales: $157,054.
- All cash sales occurred at $15.5668 per share on 2026-02-23.
- Additional non-cash 'M' transactions (likely share releases or plan dispositions) totaling 18,125 shares across the three executives.
Financial Impact
$157,054 in insider selling over 7 days
Risk Factors
- Insider selling may indicate lack of confidence in near-term prospects.
- Potential for negative newsflow ahead (e.g., trial delays, funding concerns) not yet public.
- Non-cash 'M' transactions could signal broader equity disposition plans.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-KALV-1771980228290 |
Track record
12 reports on KALV
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +4.15% at T+5 after the Apr 17, 2026 report. 3 of 5 went positive at some point.
Filters
- Jun 22, 202621w ago 15-12G Bearish 7/10 No price data
- Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $27.00 No price data
- Jun 11, 202622w ago 8-K Neutral 5/10 Entry $26.99 No price data
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $27.00 No price data
- May 19, 202625w ago Insider Cluster Bearish 5/10 Entry $26.81 to $26.79 ▲ +0.07% +1.31% vs SPY
- May 19, 202625w ago Insider Cluster Neutral 2/10 Entry $26.81 to $26.79 ▼ −0.07% −1.31% vs SPY
- Apr 29, 202628w ago 8-K Bullish 8/10 Entry $26.67 to $26.71 ▲ +0.15% −2.96% vs SPY
- Apr 17, 202630w ago Insider Cluster Bearish 6/10 Entry $20.48 to $19.63 ▲ +4.15% +4.71% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 6/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 7/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers